137 related articles for article (PubMed ID: 16370383)
1. Technology evaluation: NeuroVax, Immune Response Corp.
Darlington CL
Curr Opin Mol Ther; 2005 Dec; 7(6):598-603. PubMed ID: 16370383
[TBL] [Abstract][Full Text] [Related]
2. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
[TBL] [Abstract][Full Text] [Related]
3. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis.
Bourdette DN; Edmonds E; Smith C; Bowen JD; Guttmann CR; Nagy ZP; Simon J; Whitham R; Lovera J; Yadav V; Mass M; Spencer L; Culbertson N; Bartholomew RM; Theofan G; Milano J; Offner H; Vandenbark AA
Mult Scler; 2005 Oct; 11(5):552-61. PubMed ID: 16193893
[TBL] [Abstract][Full Text] [Related]
4. Gaboxadol. Lundbeck/Merck.
Huckle R
Curr Opin Investig Drugs; 2004 Jul; 5(7):766-73. PubMed ID: 15298075
[TBL] [Abstract][Full Text] [Related]
5. GW-1000. GW Pharmaceuticals.
Smith PF
Curr Opin Investig Drugs; 2004 Jul; 5(7):748-54. PubMed ID: 15298072
[TBL] [Abstract][Full Text] [Related]
6. FluBlok, a recombinant influenza vaccine.
Huber VC; McCullers JA
Curr Opin Mol Ther; 2008 Feb; 10(1):75-85. PubMed ID: 18228185
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: Onyvax-P, Onyvax.
Doehn C; Böhmer T; Jocham D
Curr Opin Mol Ther; 2005 Oct; 7(5):511-9. PubMed ID: 16248287
[TBL] [Abstract][Full Text] [Related]
8. Vaccine clinical trials--a statistical primer.
Mehrotra DV
J Biopharm Stat; 2006; 16(4):403-14. PubMed ID: 16892903
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.
Assaf C; Sterry W
Curr Opin Mol Ther; 2007 Apr; 9(2):197-203. PubMed ID: 17458175
[TBL] [Abstract][Full Text] [Related]
10. Technology evaluation: desmoteplase, PAION/Forest.
Debens T
Curr Opin Mol Ther; 2004 Oct; 6(5):567-75. PubMed ID: 15537059
[TBL] [Abstract][Full Text] [Related]
11. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
Darlington C
Curr Opin Mol Ther; 2007 Aug; 9(4):398-402. PubMed ID: 17694453
[TBL] [Abstract][Full Text] [Related]
12. BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis.
Correale J; Fiol M
Curr Opin Mol Ther; 2009 Aug; 11(4):463-70. PubMed ID: 19649992
[TBL] [Abstract][Full Text] [Related]
13. Technology evaluation: AVI-4126, AVI BioPharma.
Stephens AC
Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
Lopez-Diego RS; Weiner HL
Nat Rev Drug Discov; 2008 Nov; 7(11):909-25. PubMed ID: 18974749
[TBL] [Abstract][Full Text] [Related]
15. Inducible expression of antigens in plants: a study focused on peptides related to multiple sclerosis immunotherapy.
Arevalo-Villalobos JI; Govea-Alonso DO; Bañuelos-Hernández B; González-Ortega O; Zarazúa S; Rosales-Mendoza S
J Biotechnol; 2020 Jul; 318():51-56. PubMed ID: 32387449
[TBL] [Abstract][Full Text] [Related]
16. The right combination.
Nature; 2006 Jan; 439(7075):390-1. PubMed ID: 16437083
[No Abstract] [Full Text] [Related]
17. Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction.
Heading CE
Curr Opin Investig Drugs; 2007 Jan; 8(1):71-7. PubMed ID: 17263188
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of multiple sclerosis with Margulis-Shubladze vaccine].
BLAZHKO II; GRIGORASH SN
Zh Nevropatol Psikhiatr Im S S Korsakova; 1954 Mar; 54(3):263-7. PubMed ID: 13170748
[No Abstract] [Full Text] [Related]
19. Technology evaluation: EMD-273063, EMD Lexigen.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2004 Oct; 6(5):559-66. PubMed ID: 15537058
[TBL] [Abstract][Full Text] [Related]
20. Chelatotherapy in multiple sclerosis. Open preliminary study of a new therapeutical principle applied in multiple sclerosis--public health topic.
Dinu R; Dinu I
Sante Publique (Bucur); 1985; 28(1):3-30. PubMed ID: 3938075
[No Abstract] [Full Text] [Related]
[Next] [New Search]
